Fig. 5

Sequence-dependent antiproliferative effects of the combined treatment of Sora with Rsv on SW1116 (A) and SW837 (B) human colorectal cancer cell lines. Cell lines were treated with a combination of Sora (0–10 μM) and Rsv (40 and 80 μM) in (a) sequential, (b) inverted sequential or (c) simultaneous manners. Cell growth was analysed using the MTT assay. (Ab) SW1116, inverted sequential treatment [Sora + Rsv (40 µM)] vs. Sora, *P < 0.05. (Ab) SW1116, inverted sequential treatment [Sora + Rsv (80 µM)] vs. Sora, ^**P < 0.05. (Bb) SW837, inverted sequential treatment (6–10 µM). Sora vs. [Sora + Rsv (40 µM)] or [Sora + Rsv (80 µM)], ***P < 0.05. (Bc) SW837, simultaneous treatment [Sora (0.25–4 µM) + Rsv (40 µM)] or [Sora (0.25 − 4 µM) + Rsv (80 µM)] vs. Sora, + P < 0.05. (Bc) Sora (6–10 µM) vs. simultaneous treatment with Sora [Sora (6–10 µM) + Rsv (40 µM)], +  + P < 0.05. Sora, sorafenib, Rsv, resveratrol